

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

71

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :	(11) International Publication Number:
C07H 21/00	WO 91/06556
A1	(43) International Publication Date: 16 May 1991 (16.05.91)

(21) International Application Number: PCT/US90/06090

(22) International Filing Date: 24 October 1990 (24.10.90)

(30) Priority data:
425,857 24 October 1989 (24.10.89) US(71) Applicant: GILEAD SCIENCES, INC. [US/US]: 344
Lakeside Drive, Foster City, CA 94404 (US).(72) Inventors: BUHR, Chris, A. : 870 Campus Drive, No. 303,
Daly City, CA 94015 (US). MATTEUCCI, Mark : 1524
Columbus Avenue, Burlingame, CA 94010 (US).(74) Agents: MURASHIGE, Kate, H. et al.: Irell & Manella,
545 Middlefield Road, Suite 200, Menlo Park, CA 94025
(US).(81) Designated States: AT (European patent), AU, BE (Euro-
pean patent), CA, CH (European patent), DE (Euro-
pean patent), DK (European patent), ES (European pa-
tent), FR (European patent), GB (European patent), GR
(European patent), IT (European patent), JP, KR, LU
(European patent), NL (European patent), SE (Euro-
pean patent).Published
With international search report.

(54) Title: 2' MODIFIED OLIGONUCLEOTIDES

(57) Abstract

Oligomers which have substituents on the 2' position are resistant to oligonucleases and furthermore can be derivatized to deliver reagents or drugs, to carry label, or to provide other properties.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo			SN	Senegal
CH	Switzerland	KR	Republic of Korea	SU	Soviet Union
CI	Côte d'Ivoire	LI	Liechtenstein	TD	Chad
CM	Cameroon	LK	Sri Lanka	TC	Togo
DE	Germany	LL	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

-1-

5

2' MODIFIED OLIGONUCLEOTIDES10 Technical Field

The invention relates to modified oligo-nucleotides useful in technologies which rely on complementarity or specificity of oligomer sequences for drug delivery or for direct interference with nucleic acid
15 activity. More specifically, the invention concerns oligomers derivatized at the 2' position, which are stable to nuclease activity.

Background Art

20 There has been considerable activity in recent years concerning the design of nucleic acids as diagnostic and therapeutic tools. One aspect of this design relies on the specific attraction of certain oligomer sequences for nucleic acid materials in vivo which mediate disease
25 or tumors. This general approach has often been referred to as "anti-sense" technology. An oversimplified statement of the general premise is that the administered oligomer is complementary to the DNA or RNA which is associated with, and critical to, the propagation of an
30 infectious organism or a cellular condition such as malignancy. The premise is that the complementarity will permit binding of the oligomer to the target nucleic acid, thus inactivating it from whatever its ordinary function might have been.

35 A simple illustration would be the administration of a DNA oligomer complementary to an mRNA which

-2-

encodes a protein necessary to the progress of infection. This administered DNA would inactivate the translation of the mRNA and thus prevent the formation of the protein. Presumably the DNA could be directly administered, or
5 could be used to generate an mRNA complement to the target mRNA in situ. There is by now extensive literature concerned with this general approach, and the methods of utilizing oligomers of this type which are complementary to target RNA or DNA sequences are set forth, for example,
10 in van der Krol, A.R., et al., Biotechniques (1988) 6:958-976; Stein, C.A., et al., Cancer Research (1988) 48:2659-2668; Izant, J.G., et al., Science (1985) 229:345-352; and Zon, G., Pharmaceutical Research (1988) 5:539-549, all incorporated herein by reference. In addition, a
15 bibliography of citations relating to anti-sense oligonucleotides has been prepared by Dr. Leo Lee at the Frederick Cancer Research Facility in Frederick, MD.

There are two conceptual additions to the general idea of using complementarity to interfere with
20 nucleic acid functionality in vitro. The first of these is that strict complementarity in the classical base-pairing sense can be supplemented by the specific ability of certain oligonucleotide sequences to recognize and bind sequences in double-helical DNA and to insert itself into
25 the major groove of this complex. A fairly recent but reasonably definitive series of papers has elucidated the current rules for such specificity. These papers take account of very early work by, for example, Arnott, S., et al., J Mol Biol (1974) 88:509-521, which indicates the
30 general principle of binding as triplexes poly-dT/poly-dA/poly-dT, and the corresponding analogous triplex involving poly-dC as summarized by Moser, H.E., et al., Science (1987) 238:645-650. More recent studies show that the earlier rule (which was that recognition could be achieved
35 by a homopyrimidine oligomer to homopurine/homopyrimidine stretches in the duplex) could be extended to patterns

-3-

whereby mixed sequences can also be recognized (Griffin, L.C., et al., Science (1989) 245:907-971. Further summaries of these phenomena are given, for example, in a review article by Maher III, L.J., et al., Science (1989) 245:725-730. Additional related disclosures of triple-helix formation are those by Cooney, M., et al., Science (1988) 241:456-459; Francois, J.-C., Nucleic Acids Res (1988) 16:11431-11440; and Strobil, S. A., et al., J Am Chem Soc (1988) 110:7927-7929. While further details are needed to provide exact sequence specificity studies in this context, it is clear that the rules for "complementarity" in this sense of specific embedding into the major groove of the double-helix are rapidly emerging.

The second aspect of anti-sense technology which deviates from the simple concept of base-pair complementarity in native oligonucleotides results from the early recognition that oligonucleotides, especially RNAs, are highly susceptible to nuclease cleavage in biological systems. In order for these materials to remain active drugs, it would be necessary to stabilize the administered oligonucleotides against this degradation. The approach that has so far been used has been to modify the phosphodiester linkages so as to be resistant to attack by these enzymes. In particular, the phosphodiester linkage has been replaced by phosphoramidate linkages, methylphosphonate linkages, and phosphorothioate linkages. These approaches have certain results with regard to stereoisomerism and its associated impact on hybridization to the target sequences that make them less than completely satisfactory. An alternate approach has been to modify the nucleosides by using 2'-O-methyl ribose or the alpha-anomers of the conventional nucleoside residues. In addition, oligomers containing 2' amino groups have been prepared via their triphosphate analogs and enzyme-catalyzed polymerization by Hobbs, J., et al., Biochemistry (1973) 12:5138-5145. Some of these approaches


-4-

have been summarized in the Zon review cited in the previous paragraph.

The present invention provides additional 2'-substituted pentose moieties for inclusion in the oligomers useful in this technology which are resistant to nuclease activity, and may optionally be combined with additional modifications such as those set forth above.

Disclosure of the Invention

The invention is directed to nucleosides and nucleotides of the formula:



wherein

20 B is a purine or pyrimidine residue or analog thereof;

W_1 is H, $(PO_3)_m^{-2}$ wherein m is an integer of 1-3; a protecting group, or a group reactive to link hydroxyl groups;

25 W_2 is H, PO_3^{-2} , a protecting group, or a group reactive to link hydroxyl groups;


X is O, S, NR or CR_2 wherein each R is independently H or alkyl (1-6 C);

Y is a linker moiety, a drug residue optionally attached through a linker moiety, a label optionally attached through a linker moiety, or a property-affecting residue optionally attached through a linker moiety, wherein said X-Y substituent renders an oligomer in which said nucleoside or nucleotide of formula (1) is included
35 more stable to treatment with nuclease than said oligomer

-5-

which incorporates a corresponding nucleotide having $-H_2$ or $-HOH$ at the 2-position.

These materials are useful as intermediates in the synthesis of the oligomers of the invention, which are
 5 oligomers of the formula:



wherein each B is independently a purine or
 20 pyrimidine residue or analog thereof;

W_3 and W_4 are each independently H, PO_3^{-2} , a protecting group, or a group reactive to link hydroxyl groups;

n is an integer of 1-200;

25 each Z is independently a nucleotide linking residue covalently conjugating the hydroxyl groups of sequential nucleotide residues;

each A is independently selected from the group consisting of H, OH, OH derivatized to a protecting group,
 30 and X-Y wherein

X is O, S, NR, or CR_2 wherein each R is independently H or alkyl (1-5 C); and

Y is a linker moiety, a drug residue optionally attached through a linker moiety, a label optionally attached through a linker moiety, or a property-affecting
 35 group optionally attached through a linker moiety;

-6-

wherein at least one A is X-Y; and
wherein the oligomer is more stable to nuclease
than the corresponding oligomer wherein all A are H or OH.

The oligomeric materials of formula (2) are use-
5 ful as therapeutic or prophylactic agents in protocols
which are directed against infectious disease or
malignancy by targeting specific DNA and/or RNA sequences
associated with the condition, as well as in diagnostic
applications.

10

Modes of Carrying Out the Invention

A. Definitions

The oligomers of the invention contain the
15 residue of at least one nucleotide of formula (1). In
this formula, and in the oligomers, B represents a
conventional purine or pyrimidine base such as adenine
(A), thiamine (T), cytosine (C), guanine (G), or uracil
(U) or protected forms thereof. Suitable protecting
20 groups include acyl, isobutyryl, benzoyl, and the like. B
can, however, also represent a modified or protected form
or related derivative of these conventionally occurring
bases, i.e., an "analog." A wide range of these analogous
heterocyclic bases is known in the art. For example, com-
25 monly encountered among such analogs are those which
include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil,
5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine,
5-(carboxyhydroxymethyl) uracil, 5-
carboxymethylaminomethyl-2-thioridine, 5-
30 carboxymethylaminomethyluracil, dihydrouracil, beta-D-
galactosylqueosine, inosine, N6-isopentenyladenine, 1-
methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-
methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-
methylguanine, 3-methylcytosine, 5-methylcytosine, N6-
35 methyladenine, 7-methylguanine, 5-methylaminomethyluracil,
5-methoxyaminomethyl-2-thiouracil, beta-D-

-7-

mannosylqueosine, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, (acp3)w, and 2,6-diaminopurine.

As the modification of these bases affects both the stability of the resulting oligomer and the hybridization ability of the sequence, in many instances only a limited number of such substitutions in a particular oligomer is desirable. However, there are other instances when an entire oligomer may be composed of nucleotide residues containing an analog. For example, DNA polymers of uridine and oligomers of 5-bromouridine, and 5-methylcytidine have been shown to be therapeutically and diagnostically useful. As will be apparent to practitioners of the art, a sensible approach must be used in designing oligomers containing either conventional or modified base forms so that the properties of the resulting monomer are in the desired range. Therefore, in some cases, less than 10% of the bases indicated as "B" in the sequence of formula (2) will be replaced by analogous bases, preferably less than 5%, more preferably less than 1%, and most preferably none at all. However, in other cases, complete replacement by analogs is desirable.

Similar comments apply to the substitution for the bases of nonfunctional substituents such as alkyl or aryl nonheterocyclic groups; however, such substitutions may be permissible to a highly limited extent, for example one residue per 20 or so without actually destroying the functionality of the oligomer. It does not appear there is any particular advantage in making these replacements,

-8-

and they are permissible only because the replacement may be overwhelmed by the functionality of the remainder of the molecule.

Substituents designated W_1 - W_4 may be H, PO_3^{-2} , $(PO_3)_m^{-2}$, protecting groups, or groups reactive to link hydroxyl group.

A "protecting group" in the context of W is a substituent which prevents the reactivity of the -OH to which it is bound in a chemical reaction, typically a reaction to link sequential nucleotides, and which can be removed when the reaction is completed. Typical protecting groups in the compounds of the invention include 4,4'-dimethoxy trityl (DMT), 4-monomethoxytrityl and trityl.

A "group reactive to link hydroxyls" is an intermediate residue in the formation of an internucleotide link between the 5' and 3' hydroxyls. Thus, the reaction of said group with the appropriate -OH of the adjacent nucleotide results in the nucleotide linking residue, Z.

The linking residue represented by Z is typically $P(O)O^-$ in naturally occurring oligonucleotides, but can also be $P(O)S$, $P(O)NR_2$, $P(O)R$, or $P(O)OR'$, or can be CO or CNR_2 wherein R is H or alkyl (1-6C) and R' is alkyl (1-6C) or can be $-CX_2-$ wherein each X is independently an electron-withdrawing substituent as described in copending application attorney docket 4610-0005, filed on even date herewith, assigned to the same assignee and incorporated herein by reference. In general, Z can be any nucleotide linking moiety conventionally used to conjugate nucleotide residues to form oligonucleotides.

A linker moiety, as represented by Y (Y' when covalently bound to an additional substituent), is any bivalent bridging residue used to attach a desired substituent to the monomer or oligomer. The linker may be simply binding methylene groups--i.e., $-(CH_2)_n-$ or may include heteroatoms and functional groups, e.g., -

-9-

CH₂OCH₂CH₂O- or -CH₂O-CH₂CH₂NH- or -COOCH₂CH₂O-. The linker residue may also be a residue derived from a commercially available bifunctional linker such as the hetero- and homo-bifunctional linkers marketed by Pierce
5 Chemical Co., Rockford, IL.

A "drug residue," represented by Y, is the attached portion of a drug useful in conjunction with the oligomer, such as a drug capable of intercalation or of insertion into the minor groove of a DNA-DNA or DNA-RNA
10 double helix or which can effect oligonucleotide cleavage. Examples of such drugs are set forth hereinbelow.

A "label residue" is the attached portion of a label such as a moiety containing a radioisotope, a fluorophore, a chromophore, an enzyme and the like. Such
15 labels may be desirable if this oligomer is to be used in diagnosis.

A "property-affecting" residue is a residue which, by virtue of its presence, results in changed properties of the oligomer. Such changed properties
20 include, but are not limited to, enhancement of cell permeation properties; enhancement of the ability of the oligomer to hybridize to or otherwise bind to oligonucleotide sequences and enhancement of stability to nucleases.

25 Compounds of the invention that contain groups which are negatively charged at neutral pH can be prepared as their salts. The salts are formed from inorganic bases, such as NaOH, KOH or Ca(OH)₂, or organic bases, such as caffeine, various alkylamines, TEA, and DBU.

30 Compounds of the invention that contain groups which are positively charged at neutral pH can be prepared as acid-addition salts formed from inorganic acids such as HCl, H₂SO₄ or H₃SO₄, or from organic acids such as acetic, succinic or citric.

35 Thus, the nucleotides and their corresponding oligonucleotides may exist as salts depending on the pH at

-10-

which they find themselves or at which they are prepared. The phosphate and phosphodiester moieties associated with these molecules permits the formation of basic salts such as those formed from inorganic ions such as sodium, potassium, ammonium ions, but especially divalent ions such as calcium and magnesium ions. It is possible, but less common, to form salts of these materials with organic bases such as organic amines or heterocycles.

The invention compounds differ from those of the prior art by having in the 2' position, at either chirality, a substituent which confers nuclease stability and, optionally, provides the capacity to deliver a drug, for example, a reagent which is effective to interact with duplex DNA in its minor groove, provides a label, or provides some additional property. While the remainder of the molecule in formula (2) is sometimes shown for convenience as having the features of the native oligonucleotides, and, indeed, this is often the most preferred embodiment, also included within the invention are molecules which contain the 2' extensions and substitutions of the invention, but also contain additional modifications such as replacement of one or more of the phosphodiester linkages with, for example, a phosphorothioate or methyl phosphonate linkage; a phosphoramidate linkage, including those containing organic amino substituents, such as morpholidates, replacement of all beta-anomers by the alpha-anomer, and the presence or absence of protecting groups or phosphate residues at the 5'- and 3'-termini.

At the 2' position, the invention discloses several general categories of substituents, which share a common type of linkage to the 2' carbon through a substituent selected from O, S, R and CR_2 , wherein each R is independently selected. In all embodiments, X-Y represents a substituent which is capable, by virtue of its presence, of inhibiting the cleavage of the oligomer

-11-

in which it is included by nucleases. All of the oligomers of the invention are relatively stable to nucleases.

The stability of the oligomers to nucleases can be determined using any convenient assay, but is conveniently assessed using the snake venom assay illustrated hereinbelow. This assay is conducted as follows: The assay buffer is 0.5 M Tris HCl, pH 8.0, containing 100 uM/MgCl₂. Commercially available phosphodiesterase isolated from Croatalus durissus is obtained from Boehringer Mannheim as a 50% (v/v) solution in glycerol, pH 6, with a specific activity of approximately 1.2 U/mg. One ul of the phosphodiesterase-containing solution is added to 100 ul buffer, and oligomers are tested by reconstituting 0.15 OD of oligomer in the 100 ul buffer/venom prepared above. Degradation is monitored by observing the disappearance of the 260 nm absorption of the oligomer at its characteristic retention time on HPLC, and measuring the appearance of degradation products.

The oligomers of the invention which contain at least one nucleotide residue containing the 2' substituent are more stable to nuclease as judged by the foregoing assay than the corresponding oligomer containing an unsubstituted 2' position in place of the substituted positions in the invention compounds. By comparing the rate of hydrolysis in the snake venom assay with the invention compound, with that of the corresponding oligomer which is not derivatized in the 2' position, it can be assessed whether the presence of the 2' substituent(s) stabilized the oligomer to cleavage by nucleases.

Typical embodiments of X, when its sole function is to alter the properties of the oligomer, include alkyl or alkenyl (2-20C), preferably 2-6C, which may or may not be substituted with noninterfering substituents, such as

-12-

-OH, =O, carboxyl, halo, amino groups and the like, aryl or substituted aryl (6-20C), various alkyl silyl derivatives of the formula SiR_3 (wherein each R is alkyl of 2-6C), and similar substituents which also contain
5 heteroatoms. If Y includes a linker moiety, this portion of Y (Y') will provide functional group(s) for conjugation to additional substances. For example, an embodiment of Y' of 1-20C may contain a hydroxyl, amino, mercaptyl, carboxy, keto, or other functional group or several of
10 these in combination. Typical examples include $-\text{CH}_2\text{COOH}$; $-\text{CH}_2\text{CONH}_2$; $-\text{CH}_2\text{COOEt}$; $-\text{CH}_2\text{CONHCH}_2\text{CH}_2\text{NH}_2$; and the like.

The linker moiety may be utilized to couple the nucleoside, nucleotide or residue within the oligomer to a reagent or drug, such as a drug which is known to interact
15 with the minor groove of duplex DNA or DNA/RNA. A wide variety of these reagents and substances is known and the function, *in vivo*, is generally to inactivate the DNA duplex with which these reagents interact. Typical examples of such agents include netropsin and its
20 derivatives, anthramycin, quinoxaline antibiotics, actinomycin, pyrrolo (1-4) benzodiazepine derivatives and intercalating agents.

Other drugs, besides those which seek the minor groove, may also be used. Intercalators, toxins, degradation inducers, and the like can also be used. Further-
25 more, the drug need not be linked through the linker moiety, but may be directly associated with the substituent X, depending on the chemistry of the particular drug.

Another embodiment of Y represents label option-
30 ally linked to X through a linker moiety, but also possibly directly attached, again depending on the chemistry in the particular case. Suitable labels include radioisotopes, fluorescent labels, such as fluorescein and dansyl, chromophores, enzymes and the like. A wide
35 variety of labels is known and can be used to provide

-13-

detectability when the oligomers of the invention are used as probes or in other specific binding diagnostic assays.

Finally, Y can be a substituent which confers altered properties on the oligomer. It has already been
5 noted that all of the substituents, including drugs and label, confer increased nuclease stability. However, additional properties may also be affected--for example, agents which cleave associated nucleotide chains may be attached; cell permeation enhancement may occur by virtue
10 of the substituent, or Y may enhance the hybridization of the oligomer to complementary oligonucleotides or to a DNA/DNA or DNA/RNA helix. As with all of the foregoing embodiments of Y, the activity or property-changing substituent may be directly bound to X or may be
15 conjugated through a linker moiety.

B. Preparation of the Invention Compounds

Some of the compounds of the invention which are nucleosides or nucleotides are prepared by reacting the
20 corresponding nucleotide or nucleoside having OH in the 2' position with suitable reagents to effect conversion to the substituted form. In some cases, the 2' substituent may be derived from cyclic forms of the nucleoside or nucleotide. Further conversions may be required, as il-
25 lustrated below, to activate the nucleotide or nucleoside for inclusion into the oligomer. The techniques for these conversions are generally understood in the art, as are the techniques for sequential synthesis of the oligomers.

In particular, dimers may be synthesized to
30 evaluate the effect of the 2' substituent on nuclease activity. In the formation of the dimer, the converted nucleoside or nucleotide of the invention, protected at the 5' position and containing a group reactive to link hydroxyl groups at the 3' position, is reacted with, for
35 example, thymidine or cytidine linked at the 3' position

-14-

to solid support and the resulting dimer is cleaved from the support and deprotected.

In all of the foregoing cases, conversions to change the functionality and character of the 2' substituent can be conducted either at the monomer or oligomer level. Thus, a 2' substituent which has the formula for X-Y OCH_2COOEt can be converted to an embodiment wherein the substituent is the free acid or the amide either when the ester is a substituent of the single nucleoside or nucleotide, of a dimer, or contained in the oligomeric chain.

The compounds of the invention which are oligomers are obtained by inclusion of the derivatized nucleotide or nucleoside into the oligomer using standard solid phase oligonucleotide synthesis techniques. Such techniques are commercially available for formation of both standard phosphodiester linkages and the conventional substitute linkages described above.

20 C. Utility and Administration

The compounds of the invention are useful in a manner known in the art for nuclease-inhibited, specifically complementary or binding, oligomers. As set forth above, the general methods for utilization of these compounds are known, and their application to specific diseases or conditions depends on the ascertainment of the appropriate binding specificity. The determination of this binding specificity does not affect the manner of preparation or application of the modified compounds of the invention.

Accordingly, the modified oligomers of the invention are useful in therapeutic, diagnostic and research contexts. In therapeutic applications, the oligomers are utilized in a manner appropriate for antisense therapy in general--as described above, antisense therapy as used herein includes targeting a

-15-

specific DNA or RNA sequence through complementarity or through any other specific binding means, for example, sequence-specific orientation in the major groove of the DNA double-helix, or any other specific binding mode. For such therapy, the oligomers of the invention can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.

For systemic administration, injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the oligomers of the invention are formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the oligomers may be formulated in solid form and redissolved or suspended immediately prior to use. . Lyophilized forms are also included.

Systemic administration can also be by transmucosal or transdermal means, or the compounds can be administered orally. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through nasal sprays, for example, or using suppositories. For oral administration, the oligomers are formulated into conventional oral administration forms such as capsules, tablets, and tonics.

For topical administration, the oligomers of the invention are formulated into ointments, salves, gels, or creams, as is generally known in the art.

-16-

In addition to use in therapy, the oligomers of the invention may be used as diagnostic reagents to detect the presence or absence of the target DNA or RNA sequences to which they specifically bind. Such diagnostic tests
5 are conducted by hybridization through base complementarity or triple helix formation which is then detected by conventional means. For example, the oligomers may be labeled using radioactive, fluorescent, or chromogenic labels and the presence of label bound to
10 solid support detected. Alternatively, the presence of a double or triple helix may be detected by antibodies which specifically recognize these forms. Means for conducting assays using such oligomers as probes are generally known.

In addition to the foregoing uses, the ability
15 of the oligomers to inhibit gene expression can be verified in in vitro systems by measuring the levels of expression in recombinant systems.

It may be commented that the mechanism by which the specifically-binding oligomers of the invention
20 interfere with or inhibit the activity of a target RNA or DNA is not always established, and is not a part of the invention. If the oligomer seeks, for example, a target mRNA, translation may be inhibited. In addition, by binding the target, the degradation of the mRNA message may be
25 enhanced, or the further processing of the RNA may be inhibited. By formation of a triple helix, the transcription or replication of the subject DNA may be inhibited; furthermore, reverse transcription of infectious RNA or replication of infectious DNA is interfered with. It is
30 also thought that the immune function may be modulated through physiological mechanisms similar to those induced by double-stranded RNA as exemplified by the "ampligen" system or similar to those used to suppress systemic lupus erythematosus. The oligomers of the invention are
35 characterized by their ability to target specific

-17-

oligonucleotide sequences regardless of the mechanisms of targeting or the mechanism of the effect thereof.

Finally, it is understood that the oligonucleotide can be derivatized to a variety of moieties which include, intercalators, chelators, lipophilic groups, label, or any other substituent which modifies but does not materially destroy the oligomeric character of the backbone.

The following examples are intended to illustrate but not to limit the invention. In all synthesis reactions, a dry argon atmosphere was used.

Example 1

Preparation of Nucleotides and Oligomers

(A = NHAc)

2'-N-acetaminouridine was protected at the 5'-position and made reactive at the 3'-position for formation of a phosphodiester linkage conjugating the residues in an oligomer as follows:

2'-N-Acylaminouridine. To 152 mg of 2'-N-acylamino-3',5'-O-diacyluridine (Verheyden, J.P.H., et al., Org Chem (1971) 36:250-254) (0.411 mmol) in 25 ml of MeOH was added a catalytic amount of KCN. After 15 h, 1.00 g of silica gel was added, and the reaction was concentrated. The powder was added to the top of a 20 mm column of silica gel that had been equilibrated in 5% H₂O in CH₃CN. The column was eluted with 5% H₂O in CH₃CN using standard flash chromatography conditions (Still, W.C., et al., J Org Chem (1978) 43:2923-2925). Isolation and concentration of the product afforded 59.5 mg (50.8% yield) of product.

2'-N-Acylamino-5'-O-(4,4'-dimethoxytrityl)-uridine. To 59.5 mg of 2'-N-acylamino-3',5'-O-diacyluridine (0.208 mmol) in 2.5 ml of dry pyridine (that was first concentrated from dry pyridine) was added 7.6 mg (0.229 mmol, 1.10 equiv) of 4,4'-dimethoxytritylchloride. The reaction was

-18-


stirred a room temperature for 15 h and then diluted with 3.0 ml of H_2O . The mixture was partitioned between H_2O and Et_2O , shaken and separated. The aqueous layer was extracted with Et_2O , and the combined organics were washed with 1% aqueous $NaHCO_3$, dried (Na_2SO_4), filtered, and concentrated. The residue was purified by flash chromatography on a 20 mm column using first one column volume of CH_2Cl_2 and then 8% MeOH in CH_2Cl_2 as eluants. Isolation and concentration afforded 70.7 mg of product (56.6% yield) as a colorless foam.

2'-N-Acylamino-5'-O-(4,4'-dimethoxytrityl)-uridin-3-yl-hydrogenphosphonatetriethylammonium salt. To a mixture of 132 mg of 1,2,4-triazole (1.91 mmol) and 0.476 ml of anhydrous 4-methylmorpholine (4.33 mmol) in 2.40 ml of dry CH_2Cl_2 was added 0.236 ml of a 2.0 M solution of PCl_3 in CH_2Cl_2 (0.472 mmol). The mixture was then cooled on an ice-water bath for 30 min. To this mixture was added a solution of 70.7 mg of 2'-N-acylamino-5'-O-(4,4'-dimethoxytrityl)-uridine (0.188 mmol, previously concentrated from dry pyridine) in 0.523 ml of dry pyridine, dropwise over several minutes. The reaction was stirred for 20 min and then poured onto 16.8 ml of cold 1 M aqueous triethylammonium bicarbonate (TEAB, pH = 9.0). The mixture was rapidly stirred for 15 min and then extracted with 2 x 17 ml of CH_2Cl_2 . The combined organics were washed with 11.7 ml of 1 M aqueous TEAB, dried (Na_2SO_4), filtered, and concentrated. The residue was purified by flash chromatography on a 20 mm column using one column volume of 1% TEA in CH_2Cl_2 , then one column volume of 1% TEA and 2.5% MeOH in CH_2Cl_2 , and then 1% TEA and 10% MeOH in CH_2Cl_2 . The product was isolated and concentrated. The residue was partitioned between CH_2Cl_2 and 1 M aqueous TEAB, shaken and separated. The organic layer was dried (Na_2SO_4), filtered and concentrated. The product was concentrated from dry CH_3CN affording 41.9 mg (43.6% yield) of product as a slightly yellow foam.

-19-

The resulting title compound is coupled into oligomers using the method of Froehler, B.C., et al., Nucleic Acids Res (1986) 14:5399-5407.

5

Example 2Preparation of Nucleotides and Oligomers

2'-S-phenylcytidine was prepared from 2,2'-anhydro-(1-B-D-arabinofuranosyl) cytosine-HCl (a cyclic nucleoside) by suitable treatment with thiophenol. The -NH₂ of cytosine and 5'-hydroxy were protected and the 3'-OH activated as follows:

2'-S-Phenylthiocytidine. To a solution of 500 mg (1.91 mmol) of 2,2'-anhydro-(1-B-D-arabinofuranosyl)-cytosine hydrochloride (purchased from Sigma) in 50 ml of dry DMF and 1.86 ml of dry TEA (13.3 mmol) was added 0.980 ml (9.54 mmol, 5.0 equiv) of thiophenol. The reaction was stirred for 5 h and then concentrated. The residue was concentrated from MeOH onto 2.00 g of silica gel. The powder was added to the top of a 30 mm column of silica gel that was equilibrated with CH₂Cl₂. The column was then eluted with one column volume of CH₂Cl₂, then one column volume of 6.25% MeOH in CH₂Cl₂, then one column volume of 12.5% MeOH in CH₂Cl₂, and then 25% MeOH in CH₂Cl₂. Concentration of the product fractions afforded 529 mg (82.5% yield) of product as a near colorless oil.

N⁴-Benzoyl-2'-S-phenylthiocytidine. The method of transient protection (Ti, G.S., et al., J Am Chem Soc (1982) 104:1316-1319) was used to prepare the title compound. To 429 mg (1.28 mmol) of 2'-S-phenylthiocytidine (first concentrated from dry pyridine) in 12.2 ml of dry pyridine that was cooled on an ice-water bath was added 0.832 ml (6.56 mmol) of chlorotrimethylsilane. The reaction was stirred for 15 min, and then 0.767 ml (6.61 mmol) of benzoyl chloride was

-20-

added. The ice bath was removed and stirring continued for 2.5 h. The reaction was again cooled on an ice-water bath, and 2.56 ml of H₂O added. The reaction was stirred for 5 min, and then 2.56 ml of concentrated aqueous NH₄OH was added. Stirring was continued for 30 min, and then the mixture was partitioned between EtOAc and H₂O, shaken and separated. The aqueous layer was extracted with EtOAc, and the combined organics were washed with H₂O, dried (Na₂SO₄), filtered, and concentrated. The residue was purified by flash chromatography on a 30 mm column using one column volume of CH₂Cl₂ and then 5% MeOH in CH₂Cl₂ as eluants. Concentration of the product fractions afforded 138 mg (32.2% yield) of product as an oil.

5'-O-(4,4'-Dimethoxytrityl)-2'-S-phenylthio
cytidine. To 138 mg (0.314 mmol) of N⁴-benzoyl-2'-S-phenylthiocytidine (that was first concentrated from dry pyridine) in 2.00 ml of dry pyridine was added 128 mg (0.377 mmol, 1.2 equiv) of 4,4'-dimethoxytritylchloride. The reaction was stirred for 18 h at room temperature and then diluted with 2.00 ml of H₂O. The mixture was partitioned between Et₂O and H₂O, shaken and separated. The aqueous layer was extracted with Et₂O, and the combined organics washed with 1% aqueous NaHCO₃, dried (Na₂SO₄), filtered, and concentrated. The crude product was purified by flash chromatography on a 30 mm column using one column volume of CH₂Cl₂, then 2.5% MeOH in CH₂Cl₂, and then 5% MeOH in CH₂Cl₂ as eluants. Concentration of the product fractions afforded 206 mg (88.4% yield) of product.

5'-O-(4,4'-Dimethoxytrityl)-2'-S-phenylthiocytidin-3'-yl-hydrogenphosphonate triethylammonium salt. The preparation of this hydrogenphosphonate was the same as that described above except that 206 mg (0.278 mmol) of 5'-O-(4,4'-dimethoxytrityl)-2'-S-phenylthiocytidine was used, and the reagents were adjusted to the 0.278 mmol scale. After the

-21-

TEAB workup, the organics were washed with 1 M aqueous TEAB, dried (Na_2SO_4), filtered, and concentrated. The residue was purified on a 30 mm column using one column volume of 2% TEA in CH_2Cl_2 , then 2% TEA and 5% MeOH in CH_2Cl_2 , and then 2% TEA and 10% MeOH in CH_2Cl_2 as eluants. The product fractions were concentrated to a foam which was partitioned between CH_2Cl_2 and 1 M aqueous TEAB, shaken, and separated. The organic layer was dried (Na_2SO_4), filtered, and concentrated. The product was concentrated from dry CH_3CN affording 165 mg (65.5% yield) of product as a foam.

The resulting title compound is coupled into oligomers using the method of Froehler, B.C., et al., Nucleic Acids Res (1986) 14:5399-5407.

Example 3

Preparation of Additional Nucleotides and Oligomers

A. ($\text{A} = \text{OCH}_2\text{COOEt}$)

The 2'-derivatized nucleoside was prepared from N^4 -benzoyl-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-cytidine by reaction with ethyl iodoacetate and deprotection of the 2' and 5' hydroxyls. The 5' position was protected and the 3' position converted to a group reactive to link hydroxyl groups.

N^4 -Benzoyl-2'-O-(ethoxycarbonylmethyl)-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-cytidine. The preparation of this compound was an adaptation of a similar reaction used for the preparation of the 2'-OMe (Inoue, H., et al., Nucleic Acids Res (1987) 15:6131-6149). To 250 mg of N^4 -benzoyl-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-cytidine (Markiewicz, W.J., J Chem Res (1979) 181-196; (0.424 mmol; first concentrated from benzene) was added 1.00 ml (8.45 mmol, 19.9 equiv) of ethyl iodoacetate, followed by 294 mg of Ag_2O (1.27 mmol, 2.99 equiv). The mixture was rapidly

-22-

stirred and heated at 42°C for 32 h. The mixture was then filtered and concentrated. The residue was taken up in CH₂Cl₂, treated with H₂S, and concentrated. The dark residue was purified by flash chromatography on a 25 mm column using one column volume of CH₂Cl₂, then one column volume of 2.5% MeOH in CH₂Cl₂, and the 5% MeOH in CH₂Cl₂ as eluants. Concentration of the product fractions afforded 270 mg (94.4% yield) of product as a foam.

N⁴-Benzoyl-2'-O-(ethoxycarbonylmethyl)-cytidine.

- 10 To 170 mg of N⁴-benzoyl-2'-O-(ethoxycarbonylmethyl)-3',5'-O-(tetraisopropylidisiloxane-1,3-diyl)-cytidine (0.252 mmol) in 1.70 ml THF was added 0.126 ml of a 1.0 M solution of tetrabutylammonium fluoride in THF (0.126 mmol, 0.50 equiv). The reaction was stirred at room temperature for 70 min. Then 3.4 ml of pyridine/EtOH/H₂O 3/1/1 (v/v/v) was added and stirring continued for 5 min. Then approximately 10 ml of Amberlyst A-21 ion-exchange resin (pyridinium form) was added and stirring continued for 5 min. The mixture was filtered, and the resin rinsed with EtOH. The combined filtrates were concentrated. The residue was then concentrated from EtOH onto 1.00 g of silica gel. This powder was loaded onto the top of a 25 mm column of silica gel that had been equilibrated with CH₂Cl₂. The column was eluted with one column volume of CH₂Cl₂, then one column volume of 2.5% MeOH in CH₂Cl₂, and then 5% MeOH in CH₂Cl₂. Concentration of the product fractions afforded 40.7 mg (37.6% yield) of product as an oil.

N⁴-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-

- 30 (ethoxycarbonylmethyl)-cytidine. To 40.7 mg of N⁴-benzoyl-2'-O-(ethoxycarbonylmethyl)-cytidine (0.0939 mmol, first concentrated from dry pyridine) in 1.00 ml dry pyridine was added 38.3 mg of 4,4'-dimethoxytritylchloride (0.113 mmol, 1.2 equiv). The reaction was stirred at room temperature for 20 h and then diluted with 0.50 ml of H₂O. The mixture was partitioned between Et₂O and H₂O, shaken

-23-

and separated. The aqueous layer was extracted with Et₂O. The combined organics were washed with 1% aqueous NaHCO₃, dried (Na₂SO₄), filtered, and concentrated. The residue was purified by flash chromatography on a 20 mm column using one column volume CH₂Cl₂, then 2.5% MeOH in CH₂Cl₂, and then 5.0% MeOH on CH₂Cl₂ as eluants. Concentration of the product fractions afforded 55.2 mg (79.9% yield) of product.

N⁴-Benzoyl-5'-O-(5,5'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-cytidin-3'-yl-hydrogenphosphonate triethylammonium salt. The preparation of this compound was the same as described in the earlier preparation of hydrogenphosphates except that in this case 55.2 mg (0.0750 mmol) of N⁴-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-cytidine was used, and the reagents adjusted for the 0.0750 mmol scale. After the TEAB workup, the organic layer was washed with 1 M aqueous TEAB, dried (Na₂SO₄), filtered, and concentrated. The residue was purified by flash chromatography on a 25 mm column using one column volume of 1% TEA in CH₃CN, then one column volume of 1% TEA and 5% H₂O in CH₃CN, and then 1% TEA and 10% H₂O in CH₃CN. Concentration of the product fractions afforded a foam which was partitioned between CH₂Cl₂ and 1 M aqueous TEAB, shaken, and separated. The organics were dried (Na₂SO₄), filtered, and concentrated. The product was concentrated from dry CH₃CN affording 23.8 mg (35.2% yield) of product.

The derivatized resulting compound of the previous paragraph was included in an oligomer as described above.

B. (A=OEt)

N⁴-Benzoyl-2'-O-ethyl-3',5'-O-(tetraisopropylidisiloxane-1,3-diyl)-cytidine was prepared similarly to N⁴-benzoyl-2'-O-(ethoxycarbonylmethyl)-3',5'-O-(tetraisopropylidisiloxane-1,3-diyl)-cytidine except that

-24-

iodoethane was used in place of ethyl iodoacetate. The title compound was then converted to N⁴-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-ethyl-cytidin-3'-yl-hydrogenphosphonate triethylammonium salt using the same
 5 sequence of steps as for the 2'-O-(ethoxycarbonylmethyl)-compound, and further included in oligomers as described above.

C. (A=OCH₂CH₂CH₂CH₃)
 10 N⁴-Benzoyl-2'-O-butyl-3',5'-O-
(tetraisopropylidisiloxane-1,3-diyl)-cytidine was prepared similarly to N⁴-benzoyl-2'-O-(ethoxycarbonylmethyl)-3',5'-O-(tetraisopropylidisiloxane-1,3-diyl)-cytidine except that iodobutane was used in place of ethyl iodoacetate. The
 15 title compound was then converted to N⁴-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-butyl-cytidin-3'-yl-hydrogenphosphonate triethylammonium salt using the same sequence of steps as for the 2'-O-(ethoxycarbonylmethyl)-
 20 compound, and further included in oligomers as described above.

D. (A = O-SiMe₂tBu)
5'-O-(4,4'-Dimethoxytrityl)-2'-O-t-
butyldimethylsilyluridin-3'-yl-hydrogenphosphonate DBU
 25 salt. This compound was prepared differently than described in the literature. The preparation of this compound was the same as for the above compound except that 400 mg (0.606 mmol) of 5'-O-(4,4'-dimethoxytrityl)-2'-O-t-butyldimethylsilyluridine (purchased from Peninsula
 30 Labs) was used and the rest of the conditions were scaled to the 0.606 mmol scale. After the TEAB workup, the organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was purified by flash chromatography on a 35 mm column using one column volume
 35 of 1% TEA in CH₂Cl₂, then one column volume of 1% TEA and 4% MeOH in CH₂Cl₂, and then 1% TEA and 8% MeOH in CH₂Cl₂

as eluants. The product was isolated and concentrated. The foam was partitioned between CH_2Cl_2 and 1 M aqueous 1,8-diazabicyclo[5.4.0]undec-7-ene bicarbonate (DBU bicarbonate, pH=9.0), shaken and separated. The organic layer was again washed with 50 mL of 1 M aqueous DBU bicarbonate, dried (Na_2SO_4), filtered and concentrated. The product was concentrated from dry CH_3CN affording 435 mg (81.9% yield) of product as an oil. The resulting derivative is included in an oligomer synthesized by standard methods.

Conversion of 2' Substituents in Oligomers

15 A = OCH₂COOEt ———> OCH₂COOH
 ———> OCH₂CONH₂
 ———> OCH₂CONHCH₂CH₂NH₂

20 N⁴-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-cytidin-3'-yl-hydrogenphosphonate triethylammonium salt was coupled into oligonucleotides using the hydrogen phosphonate method.

In order to generate the 2'-OCH₂CO₂H, the oligo
25 was deprotected, cleaved from the support, and the 2'-
OCH₂CO₂Et hydrolyzed to the 2'-OCH₂CO₂H using 0.1 M aque-
ous NaOH at 45°C for 4.5h.

In order to generate the 2'-OCH₂CONH₂, the above oligo containing the 2'-OCH₂CO₂Et was deprotected, cleaved from the support and the 2'-OCH₂CO₂Et converted to the 2'-OCH₂CONH₂ using NH₃ in MeOH at 45°C for 29 h.; the corresponding amide of the formula -OCH₂CONHCH₂CH₂NH₂ was prepared similarly.

-26-


Example 5
Resistance to Nuclease Activity
of the Compounds of the Invention

The ability of dimers of the compounds synthesized in Example 1 to resist the activity of nucleases was determined. The illustrated compounds of Formula 1 were coupled to an additional unmodified thymidine using standard procedures to obtain compounds of the formula:

10

15

20



The resulting dimeric compounds were tested for stability with respect to nuclease from snake venom as described above. The following results are shown in Table 1.

25

30

35

-27-

Table 1

		<u>Snake Venom</u>	
		% dimer after	Time for 100%
5	-X-Y-Z	5 min.	degradation
<hr/>			
	-H	0%	<5 min.
	-OCH ₃	20%	---
10	-SPh	75%	>140 min.
	-OCH ₂ CO ₂ H	40%	46 min.
	-OCH ₂ CONH ₂	51%	>42 min.
	-OTBS	>99%	>>140 min.
			(77% dimer
15			after 140 min.)
	-OCH ₂ CONHCH ₂ CH ₂ NH ₂	100%	>>140 min.
			(>99% dimer
			after 140 min.

20 As shown in Table 1, the addition of the substituent to the 2'-position greatly enhances the stability of the resulting dimer to nuclease cleavage.

25

30


35

-28-

Claims

1. A monomer of the formula:

5



(1)

10

wherein

B is a purine or pyrimidine residue or analog thereof;

15

W_1 is H, $(PO_3)_m^{-2}$ wherein m is an integer of 1-3; a protecting group, or a group reactive to link hydroxyl groups;

W_2 is H, PO_3^{-2} , a protecting group, or a group reactive to link hydroxyl groups;

20

X is O, S, NR or CR_2 wherein each R is independently H or alkyl (1-6 C);

Y is a linker moiety, a drug residue optionally attached through a linker moiety, a label optionally attached through a linker moiety, or a property-affecting residue optionally attached through a linker moiety, wherein said X-Y substituent renders an oligomer in which said monomer of formula (1) is included more stable to treatment with nuclease than said oligomer which incorporates a corresponding nucleotide having $-H_2$ or $-HOH$ at the 2-position.

30

2. The monomer of claim 1 wherein X is O or S.

3. The monomer of claim 1 wherein X is NR.

35

4. The monomer of claim 1 wherein X is CR_2 .

-29-

5. The monomer of claim 1 wherein Y is a nuclease-inhibiting substituent selected from the group consisting of substituted or unsubstituted alkyl(2-6C) and substituted or unsubstituted aryl (6-20C).

5

6. The monomer of claim 2 wherein Y is a nuclease-inhibiting substituent selected from the group consisting of substituted or unsubstituted alkyl(2-6C) and substituted or unsubstituted aryl (6-20C).

10

7. The monomer of claim 3 wherein Y is a nuclease-inhibiting substituent selected from the group consisting of substituted or unsubstituted alkyl(2-6C) and substituted or unsubstituted aryl (6-20C).

15

8. The monomer of claim 4 wherein Y is a nuclease-inhibiting substituent selected from the group consisting of substituted or unsubstituted alkyl(2-6C) and substituted or unsubstituted aryl (6-20C).

20

9. The monomer of claim 1 wherein Y is selected from the group consisting of $-\text{CH}_2\text{COOEt}$; $-\text{CH}_2\text{COOH}$; $-\text{CH}_2\text{CONH}_2$; and $-\text{CH}_2\text{CONHCH}_2\text{CH}_2\text{NH}_2$.

25

10. The monomer of claim 1 wherein Y is a drug residue optionally attached through a linker moiety.

11. The monomer of claim 10 wherein Y is selected from the group consisting of netropsin and its derivatives, anthramycin, quinoxaline antibiotics, actinomycin, and pyrrole (1-4) benzodiazepine derivatives optionally attached through a linker moiety.

12. The monomer of claim 1 wherein Y is a label optionally attached through a linker moiety.

35

-30-

13. The monomer of claim 1 wherein Y is a property-affecting residue optionally attached through a linker moiety.

5 14. The monomer of claim 1 wherein B is selected from the group consisting of A, T, G, C and U and the protected forms thereof.

10 15. The monomer of claim 1 wherein W_2 is a phosphonate residue.

16. The monomer of claim 1 wherein W_1 is a protecting group.

15 17. The monomer of claim 1 which is a salt of N^4 -benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-cytidin-3'-yl-hydrogen phosphonate.

20 18. The monomer of claim 1 which is a salt of 5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-uridin-3'-yl-hydrogen phosphonate.

25 19. The monomer of claim 1 which is a salt of N^6 -benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-adenin-3'-yl-hydrogen phosphonate.

30 20. The monomer of claim 1 which is a salt of N^2 -isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-guanosin-3'-yl-hydrogen phosphonate.

35 21. The monomer of claim 1 which is a salt of 5-methyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-uridin-3'-yl-hydrogen phosphonate.

-31-

22. The monomer of claim 1 which is a salt of 5-bromo-5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-uridin-3'-yl-hydrogen phosphonate.


5 23. The monomer of claim 1 which is a salt of 5-methyl-N⁴-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(ethoxycarbonylmethyl)-cytidin-3'-yl-hydrogen phosphonate.

24. The monomer of claim 1 which is a salt of
10 2'-N-acylamino-5'-O-(4,4'-dimethoxytrityl)-uridin-3'-yl-hydrogen phosphonate.

25. The monomer of claims 17-24 which is the triethylammonium salt.

15

26. An oligomer of the formula:



30 wherein each B is independently a purine or pyrimidine residue or analog thereof;

W_3 and W_4 are each independently H, PO_3^{2-} , a protecting group, or a group reactive to link hydroxyl groups;

35

-32-

n is an integer of 1-200;

each Z is independently a nucleotide linking residue covalently conjugating the hydroxyl groups of sequential nucleotide residues;

5 each A is independently selected from the group consisting of H, OH, OH derivatized to a protecting group, and X-Y wherein

X is O, S, NR, or CR₂ wherein each R is independently H or alkyl (1-6 C); and

10 Y is a linker moiety, a drug residue optionally attached through a linker moiety, a label optionally attached through a linker moiety, or a property-affecting group optionally attached through a linker moiety;

wherein at least one A is X-Y; and

15 wherein the oligomer is more stable to nuclease than the corresponding oligomer wherein all A are H or OH.

27. The oligomer of claim 2 which is a dimer or trimer.

20

28. The oligomer of claim 26 wherein Z is selected from the group consisting of P(O)O, P(O)S, P(O)NR₂, P(O)R, CO, CNR₂, wherein R is H or alkyl(1-6), P(O)OR', wherein R' is alkyl(1-6C), and CX₂^{*}, wherein each
25 X^{*} is independently an electron-withdrawing substituent.

29. The oligomer of claim 26 wherein all A have the formula X-Y.

30 30. The oligomer of claim 26 wherein at least one A has the formula X-Y and all remaining A are H or OH, or the phosphorylated form thereof.

31. The oligomer of claim 26 wherein X is O or
35 S.

-33-

32. The oligomer of claim 26 wherein X is NR.

33. The oligomer of claim 26 wherein X is CR₂.

5 34. The oligomer of claim 26 wherein Y is a nuclease-inhibiting substituent selected from the group consisting of substituted or unsubstituted alkyl(2-6C) and substituted or unsubstituted aryl(6-20C).

10 35. The oligomer of claim 31 wherein Y is a nuclease-inhibiting substituent selected from the group consisting of substituted or unsubstituted alkyl(2-6C) and substituted or unsubstituted aryl (6-20C).

15 36. The oligomer of claim 32 wherein Y is a nuclease-inhibiting substituent selected from the group consisting of substituted or unsubstituted alkyl(2-6C) and substituted or unsubstituted aryl (6-20C).

20 37. The oligomer of claim 33 wherein Y is a nuclease-inhibiting substituent selected from the group consisting of substituted or unsubstituted alkyl(2-6C) and substituted or unsubstituted aryl (6-20C).

25 38. The oligomer of claim 26 wherein Y is a drug residue optionally attached through a linker moiety.

 39. The oligomer of claim 38 wherein Y is selected from the group consisting of netropsin and its derivatives, anthramycin, quinoxaline antibiotics, actinomycin, and pyrrolo (1-4) benzodiazepine derivatives optionally attached through a linker moiety.

35 40. The oligomer of claim 26 wherein Y is a label optionally attached through a linker moiety.

-34-

41. The oligomer of claim 26 wherein Y is a property-affecting residue optionally attached through a linker moiety.

5 42. The oligomer of claim 26 wherein each B is independently selected from the group consisting of A, T, G, C and U and the protected forms thereof.

10 43. The oligomer of claim 26 which is 2'-S-phenylthiocytidylyl-(3'—>5')-thymidine.

44. The oligomer of claim 26 which is 2'-O-(ethoxycarbonylmethyl)-cytidylyl-(3'—>5')-thymidine.

15 45. The oligomer of claim 26 which is 2'-O-aminocarbonylmethyl-(3'—>5')-thymidine.

20 46. The oligomer of claim 26 which is 2'-O-(hydroxycarbonylmethyl)-cytidylyl-(3'—>5')-thymidine.

47. The oligomer of claim 26 which is 2'-O-[(2-aminoethyl)-aminocarbonylmethyl]-cytidylyl-(3'—>5')-thymidine.

25 48. The oligomer of claim 26 which is 2'-N-acylamino-2'-deoxyuridylyl-(3'—>5')-thymidine.

30 49. A method to treat diseases mediated by the presence of a nucleotide sequence which comprises administering to a subject in need of such treatment an amount of the modified oligomer of claim 26 capable of specifically binding said nucleotide sequence effective to inactivate said nucleotide sequence.

35

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 90/06790

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): C 07 H 21/00		
U.S. Cl.: 536/23, 24, 27		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
U.S. Cl.	536/23, 24, 27	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT **		
Category *	Citation of Document, 15 with indication, where appropriate, of the relevant passages 17	Relevant to Claim No. 1*
Y	US, A 4,458,066 (CARUTHERS et al.) 04 July 1984. See column 2, lines 39-45.	1-49
Y	US, A 4,828,979 (KLEVAN et al.) 09 May 1989. See entire document.	1-49
Y	WO, A 88/00201 (Smith et al) 14 January 1980. See entire document.	1-49
Y	WO, A 89/05853 (TULLIS) 29 June 1989. See entire document	1-49
<p>* Special categories of cited documents: 12</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search *	Date of Mailing of this International Search Report *	
13 December 1990	21 FEB 1991	
International Searching Authority *	Signature of Authorized Officer **	
ISA/US	<i>James O. Wilson</i>	